[{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"PAION UK LTD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ PAION UK LTD","highestDevelopmentStatusID":"9","companyTruncated":"Acacia Pharma \/ PAION UK LTD"},{"orgOrder":0,"company":"PAION UK LTD","sponsor":"University Medical Center Groningen | QPS Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"PAION UK LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAION UK LTD \/ University Medical Center Groningen | QPS Holdings","highestDevelopmentStatusID":"10","companyTruncated":"PAION UK LTD \/ University Medical Center Groningen | QPS Holdings"},{"orgOrder":0,"company":"Korea University Guro Hospital","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase IV","graph3":"Korea University Guro Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Korea University Guro Hospital \/ Hana Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Korea University Guro Hospital \/ Hana Pharm"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Daegu Catholic University Medical Center","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Daegu Catholic University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daegu Catholic University Medical Center \/ Hana Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Daegu Catholic University Medical Center \/ Hana Pharm"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Peking Union Medical College Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Wuhan Union Hospital \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"PAION UK LTD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nantes University Hospital \/ PAION UK LTD","highestDevelopmentStatusID":"8","companyTruncated":"Nantes University Hospital \/ PAION UK LTD"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seoul National University Hospital \/ Hana Pharm","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Hana Pharm"},{"orgOrder":0,"company":"Kangbuk Samsung Hospital","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kangbuk Samsung Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kangbuk Samsung Hospital \/ Hana Pharm","highestDevelopmentStatusID":"1","companyTruncated":"Kangbuk Samsung Hospital \/ Hana Pharm"}]
Find Clinical Drug Pipeline Developments & Deals for Remimazolam Besylate
Reset All
